Patents by Inventor Eric H. Kuhrts
Eric H. Kuhrts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230059124Abstract: A method for simulating the activity of the bitter taste receptor TAS2R38 using a prenylflavonoid such as xanthohumol, or an extract thereof. A method of stimulating the innate immune system and prevention of upper airway infections in the body can include a prenylflavonoid extract such as xanthohumol in a solubilized system such as a spray, mouth rinse, beverage, fast dissolving dosage form, or any other means of making contact of the molecule with the receptor in the mouth or nasal passages. Also included is a method for lengthening the lifespan of humans or animals by stimulating the TAS2R38 taste receptor with the prenylflavonoid xanthohumol.Type: ApplicationFiled: July 15, 2022Publication date: February 23, 2023Inventor: Eric H Kuhrts
-
Publication number: 20170333515Abstract: A metabolic enhancing pharmaceutical composition can include xanthohumol and curcumin, and these components can be in extract form, for example. In another example, a method of enhancing the metabolic stability of a curcumin extract in the body can include combining a curcumin extract with an extract of xanthohumol from hops.Type: ApplicationFiled: November 10, 2016Publication date: November 23, 2017Inventor: Eric H. Kuhrts
-
Publication number: 20150290266Abstract: The present invention is drawn to water-soluble compositions for providing hops constituents, particularly alpha acids, iso-alpha acids, and beta acids. A pharmaceutical gel composition can comprise a hops extract and a surfactant. Such compositions can be formulated into products for various therapeutic applications, including oral and topical uses. Such compositions can also be dissolved in water to yield a clear solution containing more dilute hops acids. The invention also provides methods of treatment comprising administering water-soluble hops compositions. The present invention is also drawn to methods for making water-soluble preparations of hops constituents.Type: ApplicationFiled: November 10, 2014Publication date: October 15, 2015Inventor: Eric H. Kuhrts
-
Patent number: 8883225Abstract: The present invention is drawn to water-soluble compositions for providing hops constituents, particularly alpha acids, iso-alpha acids, and beta acids. A pharmaceutical gel composition can comprise a hops extract and a surfactant. Such compositions can be formulated into products for various therapeutic applications, including oral and topical uses. Such compositions can also be dissolved in water to yield a clear solution containing more dilute hops acids. The invention also provides methods of treatment comprising administering water-soluble hops compositions. The present invention is also drawn to methods for making water-soluble preparations of hops constituents.Type: GrantFiled: January 8, 2013Date of Patent: November 11, 2014Assignee: Bioactives, Inc.Inventor: Eric H. Kuhrts
-
Patent number: 8609154Abstract: Disclosed is a pharmaceutical composition including a therapeutic quantity of a COX-2 inhibitor having an IC50-WHMA COX-2/COX-1 ratio ranging from about 0.23 to about 3.33 with reduced gastrointestinal and cardiovascular toxicity. Also disclosed are methods for treating osteoarthritis, rheumatoid arthritis or acute pain with less side-effects and faster onset of action utilizing the disclosed pharmaceutical composition.Type: GrantFiled: April 17, 2012Date of Patent: December 17, 2013Assignee: Metaproteomics, LLCInventor: Eric H. Kuhrts
-
Publication number: 20130245118Abstract: Methods and formulations for increasing the water solubility, stability, shelf life, and/or bioavailability of dietary fatty acids are disclosed. The formulation can comprise a dietary fatty acid, a non-ionic surfactant, a flavonoid or polyphenol, and optionally, water.Type: ApplicationFiled: July 5, 2011Publication date: September 19, 2013Inventor: Eric H. Kuhrts
-
Patent number: 8349375Abstract: The present invention is drawn to water-soluble compositions for providing hops constituents, particularly alpha acids, iso-alpha acids, and beta acids. A pharmaceutical gel composition can comprise a hops extract and a surfactant. Such compositions can be formulated into products for various therapeutic applications, including oral and topical uses. Such compositions can also be dissolved in water to yield a clear solution containing more dilute hops acids. The invention also provides methods of treatment comprising administering water-soluble hops compositions. The present invention is also drawn to methods for making water-soluble preparations of hops constituents.Type: GrantFiled: December 5, 2011Date of Patent: January 8, 2013Assignee: Bioactives, Inc.Inventor: Eric H. Kuhrts
-
Publication number: 20120076740Abstract: The present invention is drawn to water-soluble compositions for providing hops constituents, particularly alpha acids, iso-alpha acids, and beta acids. A pharmaceutical gel composition can comprise a hops extract and a surfactant. Such compositions can be formulated into products for various therapeutic applications, including oral and topical uses. Such compositions can also be dissolved in water to yield a clear solution containing more dilute hops acids. The invention also provides methods of treatment comprising administering water-soluble hops compositions. The present invention is also drawn to methods for making water-soluble preparations of hops constituents.Type: ApplicationFiled: December 5, 2011Publication date: March 29, 2012Inventor: Eric H. Kuhrts
-
Patent number: 8071136Abstract: The present invention is drawn to water-soluble compositions for providing hops constituents, particularly alpha acids, iso-alpha acids, and beta acids. A pharmaceutical gel composition can comprise a hops extract and a surfactant. Such compositions can be formulated into products for various therapeutic applications, including oral and topical uses. Such compositions can also be dissolved in water to yield a clear solution containing more dilute hops acids. The invention also provides methods of treatment comprising administering water-soluble hops compositions. The present invention is also drawn to methods for making water-soluble preparations of hops constituents.Type: GrantFiled: April 21, 2006Date of Patent: December 6, 2011Assignee: Bioactives, Inc.Inventor: Eric H. Kuhrts
-
Publication number: 20110054029Abstract: Water-soluble dietary fatty acid formulations, solutions, and methods for increasing the water solubility and/or bioavailability of dietary fatty acids, as well as methods for treating various diseases are disclosed.Type: ApplicationFiled: June 25, 2010Publication date: March 3, 2011Inventor: Eric H. Kuhrts
-
Patent number: 7279186Abstract: Disclosed are novel anti-inflammatory pharmaceutical compositions and related methods that exhibit potent and selective inhibition of the cycloooxygenase-2 (COX-2) enzyme. The formulation can comprise a hops extract that exhibits COX-2 selectivity as defined by dividing the IC50 COX-2/IC50COX-1 concentrations that are determined by testing with the William Harvey Whole Blood Assay (WHMA), and can fall within the range of 0.011 to 0.2. Such compositions may also optionally contain high levels of alpha acids and low levels of beta acids, some flavonoid compounds, and virtually no essential oils. Such compositions are useful for treating conditions that manifest as inflammatory pain, or are impacted by the COX-2 enzyme. The recited compositions are particularly beneficial for treating osteoarthritis and rheumatoid arthritis, and can be used for chronic pain with reduced gastric side-effects.Type: GrantFiled: June 12, 2006Date of Patent: October 9, 2007Assignee: Lipoprotein Technologies, Inc.Inventor: Eric H. Kuhrts
-
Patent number: 7144590Abstract: Disclosed is a novel anti-inflammatory pharmaceutical composition that exhibits potent and selective inhibition of the cycloooxygenase-2 (COX-2) enzyme. The formulation consists of a hops extract that exhibits COX-2 selectivity as defined by dividing the IC50 COX-2/IC50COX-1 concentrations that are determined by testing with the William Harvey Whole Blood Assay (WHMA), and falls in the range of 0.011 to 0.2. Such compositions may also optionally contain high levels of alpha acids and low levels of beta acids, some flavonoid compounds, and virtually no essential oils. Such compositions are useful for treating conditions that manifest as inflammatory pain, or are impacted by the COX-2 enzyme. The recited compositions are particularly beneficial for treating osteoarthritis and rheumatoid arthritis, and can be used for chronic pain with reduced gastric side-effects.Type: GrantFiled: January 9, 2003Date of Patent: December 5, 2006Inventor: Eric H. Kuhrts
-
Patent number: 6953593Abstract: Disclosed is a process for producing sustained-release powders that is fast, efficient, and economical. The process involves melting an animal or vegetable oil with a melting point above 110 degrees F. in specially designed mixer through either the work energy input of the mixer shaft itself, or a specially fitted plow type mixer equipped with a heating tank, cooling unit, jacket for hot water circulation, and heated lines with nozzles for atomizing the hot oil to be sprayed on. The entire manufacturing process can be completed in about 5-30 minutes, and results in small, sustained-release particles that are free flowing and solid at room temperature. The preferred oil is a hydrogenated soy oil with a melting point range of 145-160 degrees F. which is applied at about a 5% level by weight in a high shear mixer. Also included are sustained-release compositions for therapeutic agents such as drugs, botanicals, biological agents, fungicides, and fertilizers.Type: GrantFiled: February 1, 2000Date of Patent: October 11, 2005Assignee: Lipoprotein Technologies, Inc.Inventor: Eric H. Kuhrts
-
Publication number: 20040137096Abstract: Disclosed is a novel anti-inflammatory pharmaceutical composition that exhibits potent and selective inhibition of the cycloooxygenase-2 (COX-2) enzyme. The formulation consists of a hops extract that exhibits COX-2 selectivity as defined by dividing the IC50 COX-2/IC50COX-1 concentrations that are determined by testing with the William Harvey Whole Blood Assay (WHMA), and falls in the range of 0.011 to 0.2. Such compositions may also optionally contain high levels of alpha acids and low levels of beta acids, some flavonoid compounds, and virtually no essential oils. Such compositions are useful for treating conditions that manifest as inflammatory pain, or are impacted by the COX-2 enzyme. The recited compositions are particularly beneficial for treating osteoarthritis and rheumatoid arthritis, and can be used for chronic pain with reduced gastric side-effects.Type: ApplicationFiled: January 9, 2003Publication date: July 15, 2004Inventor: Eric H. Kuhrts
-
Publication number: 20030215506Abstract: Disclosed are creatine transport enhancing formulations of creatine with an IGF-1 modulating agent such as whey protein, colostrum, or recombinant IGF-1. The creatine and IGF-1 modulating substance are preferably in sustained-release form so as to modulate and facilitate the absorption and transport of the creatine to muscle. The sustained-release combination of creatine monohydrate and IGF-1 modulating substance enhance the supply of creatine to the muscles especially during extended athletic activity or body building. The whey protein is preferably a whey protein isolate or concentrate that contains a higher percentage of biologically active molecules such as immunoglobuline A or IGF-1. The colostrum is also preferably one containing a high percentage of IgG, such as colostrum containing from 10-40% IgG.Type: ApplicationFiled: May 17, 2002Publication date: November 20, 2003Inventor: Eric H Kuhrts
-
Patent number: 6475530Abstract: Dislcosed are methods and compositions for producing weight loss in a mammal by administration of a composition containing a weight loss effective amount of a noradrenaline stimulating compound such as ephedrine, mahuang (a plant source of ephedrine alkaloids), citrus aurantium (bitter orange), synephrine, norephedrine, psuedophedrine, a methylxanthine, such as caffeine or guarana, and a botanical COX inhibitor such as resveratrol polygonum cuspidatum, scutellaria baicalensis, turmeric, curcumin, rosmary, green tea, ocimum sanctum (holy basil), or ginger, instead of an NSAID such as aspirin, and optionally a free fatty acid reducing compound. The thermogenic formula is coupled with a growth hormone stimulating formulation containing L-arginine or L-omithine, L-lysine, and a free fatty acid reducing agent such as nicotinic acid. The thermogenic formula would preferably be administered in the daytime, and the growth hormone producing formula at nighttime.Type: GrantFiled: October 4, 2000Date of Patent: November 5, 2002Inventor: Eric H. Kuhrts
-
Publication number: 20020098239Abstract: Disclosed is a process for producing sustained-release powders that is fast, efficient, and economical. The process involves melting an animal or vegetable oil with a melting point above 110 degrees F. in specially designed mixer through either the work energy input of the mixer shaft itself, or a specially fitted plow type mixer equipped with a heating tank, cooling unit, jacket for hot water circulation, and heated lines with nozzles for atomizing the hot oil to be sprayed on. The entire manufacturing process can be completed in about 5-30 minutes, and results in small, sustained-release particles that are free flowing and solid at room temperature. The preferred oil is a hydrogenated soy oil with a melting point range of 145-160 degrees F. which is applied at about a 5% level by weight in a high shear mixer. Also included are sustained-release compositions for therapeutic agents such as drugs, botanicals, biological agents, fungicides, and fertilizers.Type: ApplicationFiled: February 1, 2000Publication date: July 25, 2002Inventor: Eric H. Kuhrts
-
Publication number: 20020068365Abstract: Disclosed are various controlled release pharmaceutical compositions that include an agent that enhances or modulates the endogenous production of nitric oxide in a mammal. Controlled release pharmaceutical compositions of L-arginine, its salts, peptides, and biological equivalents, together with methods of using the compositions are included. Also included are controlled release pharmaceutical compositions of botanical extracts that modulate or enhance the production of nitric oxide, either alone or in combination with L-arginine or its biological equivalent.Type: ApplicationFiled: July 28, 1998Publication date: June 6, 2002Inventor: ERIC H. KUHRTS
-
Patent number: 5993860Abstract: An oral-delivery pharmaceutical composition for reducing the gastric irritation effect of an NSAID in the upper GI tract of a mammal. The composition includes (a) a mucosal protective amount of a pharmaceutically-acceptable hydrocolloid gum obtainable from higher plants, (b) a dispersion-enhancing amount of another excipient and (c) a therapeutically-effective amount of an NSAID. Also disclosed is a process for preparing the composition and a method for reducing the gastric irritation effect of the NSAID by administering the composition. Also, disclosed is a composition particularly useful for preparing an aqueous suspension.Type: GrantFiled: November 13, 1997Date of Patent: November 30, 1999Assignee: Venture LendingInventors: Eric H. Kuhrts, David R. Friend, Karen Yu, Jagdish Parasrampuria
-
Patent number: 5981555Abstract: The present invention concerns composition, kits and methods for reducing the flushing effect (cutaneous erythema) of an antilipemic drug, for treating hyperlipemia, for improving the effectiveness of an anti-platelet aggregating drug (e.g., in nonresponders) and for treating thrombosis. The present compositions and kits for reducing the flushing effect and for treating hyperlipemia contain an antilipemic drug (such as niacin) and either a sustained release NSAID (such as aspirin) or an NSAID and a carboxylic acid compound other than the NSAID and antilipemic drug. The kits contain (a) pre-dosages of the NSAID and optional carboxylic acid compound and (b) an antilipemic dosage of the antilipemic drug, which optionally may be combined with NSAID and optional carboxylic acid compound in an amount effective to maintain the reduction of the flushing effect.Type: GrantFiled: September 26, 1997Date of Patent: November 9, 1999Assignees: Lipoprotein Technologies, Inc., Vanderbilt UniversityInventors: Eric H. Kuhrts, L. Jackson Roberts, II, Jason D. Morrow